US 12,030,868 B2
Prodrugs of CGRP antagonists
Charles M. Conway, Cheshire, CT (US); Gene M. Dubowchik, Middlefield, CT (US); Jeffrey Claude Pelletier, Lafayette Hill, PA (US); and Allen B. Reitz, Lansdale, PA (US)
Assigned to Pfizer Ireland Pharmaceuticals, Ringaskiddy (IE)
Appl. No. 17/283,049
Filed by Pfizer Ireland Pharmaceuticals, County Cork (IE)
PCT Filed Oct. 10, 2019, PCT No. PCT/US2019/055525
§ 371(c)(1), (2) Date Apr. 6, 2021,
PCT Pub. No. WO2020/077038, PCT Pub. Date Apr. 16, 2020.
Claims priority of provisional application 62/745,302, filed on Oct. 13, 2018.
Prior Publication US 2021/0395223 A1, Dec. 23, 2021
Int. Cl. C07D 401/14 (2006.01); C07D 498/22 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 498/22 (2013.01)] 20 Claims
 
1. A compound having General Formula 1, comprising a CGRP Parent Molecule having at least one functionalizable moiety Z:

OG Complex Work Unit Chemistry
wherein:
the CGRP Parent Molecule having at least one functionalizable moiety Z is

OG Complex Work Unit Chemistry
Z is a functionalizable moiety present on the CGRP Parent Molecule;
m is at least 1;
R1 is

OG Complex Work Unit Chemistry
or —CH2OP(═O)(OH)2;
R2 is —[C(R3)2]nR4, —NR3R4, or —OR4, wherein each R3 is independently hydrogen or C1-C10 alkyl wherein R3 are optionally connected to form a ring, and R4 is a substituted or unsubstituted C1-C20 alkyl group, a substituted or unsubstituted C2-C20 alkenyl group, a substituted or unsubstituted C2-C20 alkynyl group, a substituted or unsubstituted C1-C20 heteroalkyl group, a substituted or unsubstituted C2-C20 heteroalkenyl group, a substituted or unsubstituted C2-C20 heteroalkynyl group, a substituted or unsubstituted C3-C20 cycloalkyl group, a substituted or unsubstituted C3-C20 heterocycloalkyl group, a substituted or unsubstituted C6-C20 aryl group, or a substituted or unsubstituted C1-C20 heteroaryl group, and n is 0 or 1,
wherein, when m is at least 2, R2 are optionally connected to form a ring.